Mandate

VINGE ADVISES THE AIRPORT OPERATOR ABERTIS IN CONNECTION WITH THE SALE OF STOCKHOLM SKAVSTA AIRPORT

July 25, 2013

Vinge has advised the Spanish airport operator, Abertis Infraestructuras S.A. in connection with the sale of the British subsidiary, TBI, and its subsidiary, Stockholm Skavsta Flygplata AB. Stockholm Skavsta Flygplats is being sold together with airports in Belfast and Orlanda Sanford (Florida) airport terminal as well as TBI’s other management operations at airports in the United States to the North American airport operator, ADC & HAS Airports Worldwide. Stockholm Skavsta airport is Sweden’s third largest airport with approximately 2.5 million passengers per year. The airport has been owned by Abertis since 2005. The municipality of Nyköping will continue to hold 9.9% of the shares in Stockholm Skavsta Flygplats AB. The transaction is conditional upon approval by the relevant competition authorities and other public authorities.

Vinge’s team consisted of partner Michael Wigge together with, among others, associates Paul Dali (M&A), Johan Cederblad (real estate and environmental) and Åsa Gotthardsson (employment and pensions).

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025